ANTX AN2 Therapeutics, Inc. Insider Trading

CEO buys 10.0K shares of ANTX at $1.07; 2 prior ANTX buys both had positive 90d returns; stock now -62.8% from 52-week high.

Eric Easom, CEO, purchased 10,000 shares at $1.07 on 2025-06-02, increasing his holdings to 256,380 shares (+4.1% vs. pre-transaction). His two prior open-market buys at ANTX both generated positive 90-day returns (31.1% on 2024-11-18, 56.8% on 2023-05-15), indicating a consistent pattern of well-timed purchases at this ticker. The current stock price of $1.10 reflects a -62.8% decline from the 52-week high and -9.8% decay over the trailing 30 days, creating a substantially depressed valuation environment relative to recent history. Against this backdrop, the CEO's discretionary purchase—his third open-market buy of ANTX—aligns temporally with his prior two acquisitions' pattern of generating subsequent gains, though the company remains unprofitable with a net loss of $10,649,000 over the most recent full fiscal year and a market cap of $33,193,292.

10% Owner Leonard Braden Michael sold 2,532,000 shares (44.0% of pre-transaction holdings) for $2,872,476.80 across 4 separate sales May 28–30.

Leonard Braden Michael, a 10% owner, executed 4 separate sales totaling 2,532,000 shares for $2,872,476.80 on May 28–30, 2025, reducing his stake from 5,749,432 shares to 3,217,432 shares (a -44.0% reduction in holdings). The blended average sale price of $1.13 reflects a market environment where the stock is now trading at $1.06, down -64.2% from its 52-week high of $2.96 and -14.5% over the past 30 days. Notably, the company reported negative net income of $-10,649,000.00 and carries a market cap of $31,986,263.20, indicating financial stress. Across his cross-ticker track record, Michael's prior 20 buys averaged +643.6% return over 90 days with a 62.50% win rate, but this sale represents a material reduction in exposure to an unprofitable company during a period of significant stock decline, which stands in contrast to his historical pattern of accumulation and strong subsequent returns.

Director Margaret M FitzPatrick purchases 8,610 shares of ANTX at $1.18; company reports $-10.6M net loss.

FitzPatrick, a director, purchased 8,610 shares at $1.18 on 2025-05-28, representing her first holding in ANTX. The company reported a net income of $-10,649,000.00 and operates at a market cap of $36,512,621.20, indicating a pre-revenue or early-stage biotech profile typical of AN2 Therapeutics. The stock currently trades at $1.21, down 59.1% from its 52-week high of $2.96, suggesting the purchase occurred during a significant drawdown. This insider buy by a director during a period of substantial losses and depressed valuation relative to the 52-week range provides a data point on insider willingness to accumulate at lower prices, though the transaction size and dollar value remain modest relative to market capitalization.

Director Robin Shane purchases 60,000 shares in 6 transactions (Dec 6–10) at blended average $1.45; holdings now 652,573 shares (+10.1%).

Robin Shane, a Director at AN2 Therapeutics, completed 6 separate purchases totaling 60,000 shares for $86,708.01 over a 5-day window (Dec 6–10, 2024) at prices ranging from $1.43 to $1.49. This represents a 10.1% increase to his post-transaction holdings of 652,573 shares. The transaction occurred while the stock trades at $1.51 (current price), still down 93.0% from its 52-week high of $21.53, though it has risen 37.3% over the past 30 days and 45.2% over 90 days. The company reported a net loss of $12,747,000.00 over its most recent fiscal year with a market cap of $45,117,123.90. His prior trading activity at ANTX shows 5 recent buys in late November, though none of those outcomes are yet measurable at the 90-day mark.

Director Zakrzewski buys 2,000 ANTX shares at $1.40; stock down 93.6% from 52-week high of $21.53 amid cluster buying pattern

Joseph S Zakrzewski, a director at AN2 Therapeutics, purchased 2,000 shares at $1.40 on 2024-11-27, bringing his total holdings to 125,199 shares. This transaction is part of a cluster pattern, with 2 other insiders buying within the same 14-day window. The stock is severely depressed, trading at $1.37 versus a 52-week high of $21.53 (-93.6%), though it has recovered 24.6% over the past 30 days from lows. The company is unprofitable with negative net income of $12,747,000.00 over its most recent full fiscal year, and the market cap of $40,934,079.30 suggests a distressed biotech name. Zakrzewski's prior sale at this ticker on 2024-01-18 was well-timed by the 90-day mark (-87.0% return), but the fundamental weakness combined with extreme valuation collapse warrants scrutiny of whether this buy reflects contrarian conviction or routine rebalancing in a financially struggling entity.

Director Readnour Robin Shane bought 75,000 shares (75.0K) at $1.41–$1.42 in 4 transactions; stock -93.6% from 52-week high; unprofitable company; cluster buy pattern with 2 other insiders.

Director Readnour Robin Shane executed 4 separate purchases totaling 75,000 shares for $105,685.00 on 2024-11-26 and 2024-11-27, raising his holdings from 547,573 to 622,573 shares (+13.7%). The filing occurs as the stock trades at $1.37, down -93.6% from its 52-week high of $21.53, despite a +24.6% 30-day rebound. The company reported negative net income of $-12,747,000.00 on a market cap of $40,934,079.30, indicating material unprofitability. A cluster pattern shows 2 other insiders also bought within the past 14 days, concurrent with Shane's accumulation. This sequence of open-market purchases at depressed absolute prices warrants scrutiny given the company's unprofitable status and the stock's severe drawdown from recent highs.

Director Robin Shane buys 200,000 shares for $213,127.50 at AN2 Therapeutics; cluster buy pattern with 2 other insiders in past 14 days.

Robin Shane, a director at AN2 Therapeutics, executed 4 separate purchases totaling 200,000 shares for $213,127.50 (blended average $1.07) across November 19-20, 2024, expanding holdings from 314.8K to 514.8K shares (+63.5%). This accumulation occurs amid a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days. The company remains unprofitable with full-year net income of $-12.7M and a market cap of $36.8M, while the stock trades 94.3% below its 52-week high of $21.53 yet up 13.9% over the past 30 days. The concurrent purchases by multiple insiders at depressed valuations warrant investor attention to whether the board perceives fundamental value below current market pricing.

Director Zakrzewski purchases 25,000 shares at $1.00–$1.01 as stock trades -94.0% from 52-week high; cluster buy pattern with 2 other insiders in 14 days

Zakrzewski Joseph S, Director at AN2 Therapeutics, executed 2 purchases totaling 25,000 shares for $25,046.00 on 2024-11-18 and 2024-11-19, raising his holdings from 98,199 to 123,199 shares (+25.5%). The purchases occurred at $1.00–$1.01 while the stock currently trades at $1.30, down -94.0% from its 52-week high of $21.53. The company reported a net loss of $-12,747,000.00 over its most recent full fiscal year. Additionally, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. His prior open-market sell at this ticker in January 2024 was well-timed (90-day return -87.0%), though that historical pattern does not necessarily predict the outcome of this current purchase in a company with significant operating losses.

ANTX CEO Easom buys 50,000 shares at $1.00; stock -95.4% from 52-week high; company posted $-12.7M net income loss

Eric Easom, Chief Executive Officer of AN2 Therapeutics, purchased 50,000 shares at $1.00 on 2024-11-18, increasing his holdings to 1.07M shares. The purchase occurs when ANTX is trading at -95.4% from its 52-week high of $21.53, reflecting a severe deterioration in stock performance. The company reported a net loss of $-12.7M over its most recent full fiscal year, indicating ongoing profitability challenges. While Easom's cross-ticker track record shows 1 prior buy with a 90-day return of +56.8%, his same-ticker history at ANTX (1 prior buy on 2023-05-15) resulted in a +56.8% 90-day return, establishing a pattern of well-timed purchases at this company. The current purchase at depressed absolute price levels occurs in the context of substantial prior losses and negative near-term momentum (-4.8% over 30 and 90 days), warranting investigation into whether this reflects conviction in a turnaround or other strategic considerations.

10% owner Leonard Braden Michael bought 1,500,000 shares at $1.04; holdings rise to 5,749,432 shares.

Leonard Braden Michael, a 10% owner, purchased 1,500,000 shares at $1.04 on 2024-08-14, increasing his holdings from 4,249,432 to 5,749,432 shares—a 35.3% increase in his position. This is a material accumulation by an insider with substantial ownership stakes. The timing merits attention: the stock now trades at $1.05, having collapsed 95.1% from its 52-week high of $21.53 and declined 58.5% over the prior 30 days, suggesting the purchase occurred after significant deterioration. The company reported net income of $-14,435,000.00 for the most recent fiscal year, indicating ongoing losses with a market cap of $31,334,552.55. Across all his open-market purchases (20 prior buys at various tickers), Michael's average 30-day return was +17.3%, but this particular trade's relevance depends on whether it reflects conviction in ANTX's recovery potential or a capital allocation decision tied to other strategic factors.